Roche Solves BM's Strategic Dilemma
Torn by internal struggles, the family that controlled Boehring Mannheim faced two challenges: dealing with the battle for control by family members and fighting off the anticipated threat to its profitable glucose testing business from Abbott's recent acquisition of MediSense. Roche's bid solves both problems, giving family members the money to do what they want and providing BMS' diagnostic business with a broader technology context.
You may also be interested in...
The year-old union of bioMerieux-Pierre Fabre appears to be on the verge of disintegrating, amid lack of a coherent strategy, disagreements between the two founders who spearheaded the deal, and departure of key top executives. The company won't comment except to say that it is considering various alternatives including a break-up. Unraveling should not be difficult, since the two companies haven't integrated much. And the separation would leave bioMerieux, now the world's eighth largest diagnostics company, and Pierre Fabre, one of France's largest independent pharmaceutical companies, free to seek more appropriate solutions to the challenges they face.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.